Phase III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer

Trial summary:

The PATHOS trial aims to examine whether reducing the intensity of adjuvant treatment following transoral surgery (transoral laser microsurgery (TLM) or transoral robotic surgery (TORS)) in Human Papillomavirus (HPV) related Oropharyngeal Squamous Cell Cancer (OPSCC) patients will result in improved swallowing outcomes, whilst maintaining local control rates and survival. The trial aims to recruit 1100 patients from UK and international centres until the end 2024.

RT QA summary:

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.

QA ProcessQA ActivityRequired for TrialAdditional Details
Pre-AccrualFacility Questionnaire
Outlining Benchmark Case2 cases
Planning Benchmark Case2 cases
Dummy Run
During AccrualIndividual Case ReviewProspective review of first lateralised and non-lateralised patient
Data collectionAll patients
QA StreamliningCompARE, TORPEdO, BEST OF

RTTQA contact:

Chief investigator: Prof Mererid Evans / Prof Terence Jones

RT Lead: Dr Nachi Palaniappan, Dr Matthew Beasley, Dr Richard Webster

Sponsor: Velindre University NHS Trust & Cardiff University,

Funder: Cancer Research UK